GlassScriptPhysician profile
Mahmood Abedi
NPI 1649255233
$12,163.46
in general payments reported to CMS, 2019-2025
42 companies · $3,310 in 2025
The $3,310 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $616 · 2021: $950 · 2022: $1,234 · 2023: $2,476 · 2024: $2,687 · 2025: $3,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,368 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,368.06 |
| Education | $104.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,597.47 | 2019-2025 | Rinvoq, Linzess, Skyrizi |
| Janssen Biotech, INC. | $1,481.54 | 2019-2025 | Tremfya, Stelara, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,181.78 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Pfizer INC. | $770.38 | 2019-2025 | |
| Celgene Corporation | $748.66 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $699.87 | 2019-2025 | Xifaxan, Trulance |
| Boston Scientific Corporation | $595.60 | 2019-2021 | |
| Qol Medical, LLC | $444.10 | 2019-2025 | Sucraid, Sucraid |
| Madrigal Pharmaceuticals | $271.12 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $268.71 | 2023-2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $229.00 | 2024-2025 | Iqirvo, Bylvay |
| Ironwood Pharmaceuticals, INC | $225.54 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $220.62 | 2022-2025 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $200.58 | 2024-2025 | Zenpep, Vowst |
| Gilead Sciences, INC. | $197.57 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $170.23 | 2023-2025 | |
| Ardelyx, INC. | $164.61 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $161.05 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $148.30 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Amgen INC. | $142.78 | 2021-2025 | Avsola, Amjevita, Uplizna |
| Nestle Healthcare Nutrition INC. | $141.11 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $122.17 | 2021-2023 | Rebyota |
| Intercept Pharmaceuticals, INC. | $115.02 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $98.03 | 2024 | Voquezna |
| Olympus America INC. | $82.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $76.95 | 2023-2025 | Dupixent |
| Shionogi INC | $74.01 | 2019-2020 | |
| Angiodynamics, INC. | $71.51 | 2019 | |
| Ucb, INC. | $61.34 | 2019 | |
| Pharmacosmos Therapeutics INC. | $58.15 | 2025 | Monoferric |
| Daiichi Sankyo INC. | $54.44 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $51.93 | 2024-2025 | Givlaari |
| Janssen Scientific Affairs, LLC | $43.64 | 2023 | Stelara |
| E.R. Squibb & Sons, L.L.C. | $41.29 | 2022-2024 | Zeposia |
| Vibrant Gastro, INC. | $31.10 | 2024 | Vibrant Starter Kit |
| Merck Sharp & Dohme LLC | $26.21 | 2023 | Dificid |
| Biocon Biologics INC | $19.62 | 2025 | Yesintek |
| Vivus LLC | $17.91 | 2020 | |
| W. L. Gore & Associates, INC. | $16.64 | 2023 | Gore Cardioform Septal Occluder |
| Albireo Pharma, INC. | $15.74 | 2022 | |
| Alfasigma USA, INC. | $13.33 | 2020 | |
| Allergan, INC. | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Abedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.